The European Medicines Agency has approved a new drug that can slow the progression of Alzheimer’s disease. According to Professor Dr Sebastiaan Engelborghs, Co-Chair of the Scientific Panel on Dementia & Cognitive Disorders at the European Academy of Neurology, this marks a significant breakthrough. “This allows us to enter a new era in the treatment of Alzheimer’s disease.”
Sebastiaan Engelborghs commented on the recent decision by the European Medicines Agency to approve the drug lecanemab for the treatment of Alzheimer’s disease.